KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Total Current Liabilities (2019 - 2025)

GoodRx Holdings' Total Current Liabilities history spans 7 years, with the latest figure at $246.0 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 98.54% year-over-year to $246.0 million; the TTM value through Dec 2025 reached $246.0 million, up 98.54%, while the annual FY2025 figure was $246.0 million, 98.54% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $246.0 million at GoodRx Holdings, up from $181.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $246.0 million in Q4 2025 and bottomed at $59.4 million in Q1 2022.
  • The 5-year median for Total Current Liabilities is $93.7 million (2022), against an average of $104.7 million.
  • The largest YoY upside for Total Current Liabilities was 98.54% in 2025 against a maximum downside of 11.28% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $81.1 million in 2021, then decreased by 5.91% to $76.3 million in 2022, then surged by 60.59% to $122.6 million in 2023, then increased by 1.1% to $123.9 million in 2024, then skyrocketed by 98.54% to $246.0 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Total Current Liabilities are $246.0 million (Q4 2025), $181.9 million (Q3 2025), and $130.9 million (Q2 2025).